Design (Testphase)
Growth
Ben Bennett: Focus List
41
Hits
August 3, 2026
last calculated
Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Ben Bennett's Focus List: quality growth stocks in strong industries. The industry ranks in the top 40 by 12-month strength, expected earnings per share (EPS) growth for next year is above 25%, revenue grew by an average of more than 30% over the last 2 quarters, price above $10, and sufficiently liquid (~250K shares).
Global filters: market cap of $50B or less (mega caps are cut from every scanner); 10- and 30-day ADR must be ≥ 1% (too little movement gets cut); names after a reverse split (distorted price history) and names with a red Stress RS (rating ≤ 30 — weak on stress days) are excluded.
🔔 Watch scanner
Terms in This Scanner Explained
(16)
- ADR (Average Daily Range)
- The average daily swing of a stock in percent - measured over 10 or 30 trading days (columns "ADR 10D/30D"). An ADR of 5% means: on a normal day the gap between the intraday low and high runs about 5%. Traders look for movement - that is why stocks with an ADR under 1% are filtered out globally. Not to be confused with ADR meaning "American Depositary Receipt" (a US certificate for foreign shares) - here ADR always means the daily swing.
- AI Classification
- Our company-by-company assessment of the AI boom based on SEC filings (the last four quarterly 10-Q reports and two annual 10-K reports): "Sells AI" (AI is a revenue source), "Threatened" (AI is a concrete business risk), "Uses AI" (operational use), or "Neutral" (no material AI exposure). Every classification requires at least two direct quote citations - otherwise the column shows "-". Not a quality judgment or a buy recommendation; the full file is on the stock page, methodology at /stocks/ai-rating-methodology.
- Analysis (Full Company Analysis)
- If the Analysis column shows "Read," there is an in-depth TickerGuard company analysis for this stock: business model, scanner findings, quarterly results, evidence from SEC filings, plus opportunities and risks. One click opens it directly.
- Avg/Yr 3Y (Average Annual Return)
- The stock's average annual return over the past 3 years. Shows at a glance whether a stock delivers over the long run or just had a short hot streak.
- Earnings Date
- The date of the next quarterly earnings report. Price gaps in either direction are common around this date - that is why we color it red when it is 7 days away or less, and yellow when it is 14 days away or less: elevated risk for fresh positions.
- EPS (Earnings per Share)
- Quarterly earnings divided by the number of shares outstanding. The most important growth metric: if EPS rises strongly over several quarters, the company is earning more money per share.
- Free Cash Flow (FCF)
- Operating cash flow minus capital expenditures - the money left over for everything else (debt paydown, acquisitions, or buybacks). Consistently positive free cash flow is one of the most honest signs of a healthy business model.
- Funda Rating (Fundamental Rating A+ to F)
- Our proprietary fundamental rating from 0 to 100 points with a school-grade rank from A+ to F. 50 points is the average across the universe, 100 the best possible score. Every stock is scored against all others by percentile: growth in earnings and revenue, earnings surprises, analyst estimates, and quality criteria such as margins, cash flow, and balance-sheet strength. Grades: A+ from 95, A from 75, B from 55, C from 45, D from 25, E from 5, F below — A/A+ are the fundamentally strongest stocks in the universe.
- Liquidity
- How easily a stock can be bought and sold without moving the price - measured by (dollar) volume. Illiquid stocks have wide spreads and jerky prices; that is why almost every scanner applies a minimum liquidity filter.
- Market Capitalization (Mkt Cap)
- The market value of the company: share price x total shares outstanding, shown here in billions of dollars. Micro caps (< $0.3B) are small and volatile, mega caps (> $200B) are heavyweights. Our scanner universe is deliberately capped at $50B - we look for stocks with room to run.
- Net Margin
- How much of revenue is left as profit? Net income divided by revenue, in percent. A 20% margin means: out of every dollar of revenue, 20 cents is left as profit. Rising margins are a strong quality signal.
- Operating Cash Flow (OCF)
- The cash that actually flows into the company from day-to-day operations - without accounting effects such as depreciation. A company can report book profits while still burning cash; operating cash flow reveals that.
- Piotroski F-Score
- A balance-sheet health check developed by Joseph Piotroski: 9 yes/no criteria covering earnings, cash flow, leverage, and efficiency produce a score from 0 to 9. Scores of 7 or higher are considered financially very solid, scores under 3 a warning sign.
- Sector & Industry
- Two levels of industry classification: sector is broad (e.g., Technology), industry is narrow (e.g., Semiconductors). Many strategies watch industry strength, because strong stocks are almost always found in strong industries.
- Stage (Weinstein Stages 1-4)
- Stan Weinstein divides every price chart into four stages: Stage 1 = basing (sideways after a downtrend), Stage 2 = uptrend (the only buying stage), Stage 3 = topping, Stage 4 = downtrend (avoid, or short candidate). Measured against the 30-week line (150-day moving average) and its slope.
- Stress RS (Strength on Stress Days)
- A stress day is a day on which both the overall market and the stock's own sector fell at least 0.5%. Stress RS counts on how many of these days the stock still closed green (shown as "g/n" = green days out of n stress days) and turns that into a rating from 1 to 99. High values point to buyers stepping in even on weak days - often a sign of institutional accumulation.
Hit List
Filter ▾
Rating (traffic light)
Stage
Funda Rating
Piotroski
Columns ▾
This scanner's columns
Extra columns
Tip: clicking a column header sorts the table by that column; a second click flips the direction.
| Symbol | Earnings | Avg/Y 3Y | Stress RS | Stage | Funda Rating | Piotroski | MktCap | Industry | AI Rating | Deep Dive | Deep-Dive Report | Sector | Price | YTD | 6 Mo. | 1 Year | Off High | Price Target | RS | EPS Rating | ADR 10D | ADR 30D | Beta | P/E | P/E (f) | P/S | P/B | P/FCF | PEG | EV/EBITDA | EBIT Margin | Gross Margin | Net Margin | ROE | ROA | Debt/Eq | Equity Ratio | Sales +/Y | Growth Score | Div. Yield | Payout Ratio | Altman Z | Inst. % | Short % | Analysts |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MXL MaxLinear Inc | 07/22 | +69 % | 72 7/25 | Stage 2 | B 64 | 4 of 9 | 6.0 $ | Semiconductors | Sells AI | — | Technology | 66.80 $ | +411.1 % | +518.4 % | +322.4 % | −11.1 % | +41.5 % | 99 | 8 | 10.9 % | 11.9 % | 3.93 | — | 38.5 | 10.5 | 11.9 | 1,813.6 | 0.39 | 12.3 | -12.2 % | 57.5 % | -18.2 % | -27.9 % | -4.9 % | 0.33 | 58.9 % | +29.7 % | — | 0.0 % | 0.0 % | 2.4 | 87.4 % | 6.0 % | 4.2 (11) | |
| VIAV Viavi Solutions Inc | 08/06 | +127 % | 72 7/25 | Stage 2 | C 48 | 4 of 9 | 9.3 $ | Communication Equipment | Sells AI | — | — | Technology | 37.00 $ | +180.4 % | +159.6 % | +267.7 % | −16.5 % | +74.5 % | 98 | 9 | 8.6 % | 8.4 % | 1.19 | — | 29.6 | 6.8 | 10.8 | 203.9 | 1.34 | 82.0 | 12.2 % | 60.7 % | -4.0 % | -7.0 % | 3.6 % | 7.85 | 33.5 % | +8.4 % | — | 0.0 % | 0.0 % | -85.0 | 97.3 % | 6.8 % | 3.8 (9) |
| AAOI Applied Optoelectronics, Inc. | 08/06 | +1,099 % | 92 10/25 | Stage 2 | B 62 | 4 of 9 | 7.6 $ | Communication Equipment | Sells AI | — | — | Technology | 94.30 $ | +322.9 % | +266.1 % | +312.4 % | −40.7 % | +59.4 % | 98 | 42 | 12.0 % | 12.7 % | 3.69 | — | 84.0 | 14.9 | 6.9 | — | 0.78 | 38.4 | -8.6 % | 29.6 % | -8.6 % | -6.1 % | -3.3 % | 0.16 | 70.6 % | +82.8 % | — | 0.0 % | 0.0 % | 7.6 | 68.3 % | 12.9 % | 4.2 (5) |
| AIP Arteris Inc | 08/04 | +177 % | 61 6/25 | Stage 2 | C 48 | 3 of 9 | 1.4 $ | Semiconductors | Sells AI | — | — | Technology | 29.90 $ | +165.9 % | +197.1 % | +203.0 % | −3.8 % | +27.8 % | 98 | 42 | 7.1 % | 7.5 % | 1.92 | — | 0.0 | 18.4 | 501.5 | — | — | -7.7 | -38.0 % | 88.8 % | -44.9 % | -1,369.6 % | -17.9 % | 2.11 | 1.8 % | +22.3 % | — | 0.0 % | 0.0 % | -3.7 | 61.1 % | 7.3 % | 4.5 (4) |
| STRL Sterling Construction Company Inc | 08/03 | +532 % | 48 6/29 | Stage 2 | A 82 | 7 of 9 | 19.1 $ | Engineering & Construction | Uses AI | — | — | Industrials | 596.80 $ | +191.4 % | +159.2 % | +123.0 % | −12.3 % | +58.6 % | 97 | 88 | 7.1 % | 7.5 % | 1.83 | 48.7 | 31.6 | 6.6 | 14.0 | 43.5 | 1.02 | 30.8 | 17.2 % | 23.3 % | 12.0 % | 36.7 % | 12.9 % | 0.57 | 42.7 % | +17.7 % | — | 0.0 % | 0.0 % | 6.7 | 95.7 % | 4.8 % | 5.0 (3) |
| KLIC Kulicke and Soffa Industries Inc | 08/05 | +47 % | 60 6/25 | Stage 2 | B 64 | 6 of 9 | 4.7 $ | Semiconductor Equipment & Materials | Neutral | — | Technology | 89.20 $ | +180.3 % | +179.3 % | +176.2 % | −1.4 % | +12.1 % | 97 | 6 | 7.6 % | 6.8 % | 1.63 | 81.7 | 20.8 | 6.1 | 5.4 | 1,085.3 | 2.38 | 48.1 | 15.9 % | 49.8 % | 7.2 % | 6.4 % | 3.9 % | 0.05 | 72.3 % | -7.4 % | — | 0.9 % | 54.3 % | 13.9 | 93.1 % | 6.1 % | 4.0 (5) | |
| COHU Cohu Inc | 07/30 | +21 % | 73 7/25 | Stage 2 | B 66 | 6 of 9 | 2.3 $ | Semiconductor Equipment & Materials | Sells AI | — | Technology | 48.00 $ | +176.6 % | +189.3 % | +168.7 % | −5.0 % | +47.7 % | 97 | 5 | 7.9 % | 7.4 % | 1.55 | — | 82.0 | 4.3 | 2.9 | 65.0 | 1.15 | 98.1 | -8.3 % | 44.0 % | -7.4 % | -7.0 % | -1.8 % | 0.43 | 62.3 % | +12.7 % | — | 0.0 % | 0.0 % | 8.6 | 109.5 % | 20.3 % | 4.6 (5) | |
| CRDO Credo Technology Group Holding Ltd | 09/02 | +487 % | 72 7/25 | Stage 2 | A 87 | 7 of 9 | 38.5 $ | Semiconductors | Sells AI | — | Technology | 207.00 $ | +89.0 % | +63.6 % | +85.6 % | −13.2 % | +34.9 % | 96 | 93 | 10.5 % | 11.3 % | 3.20 | 83.7 | 35.1 | 28.8 | 18.8 | 94.6 | — | 77.5 | 35.7 % | 68.0 % | 35.4 % | 34.4 % | 17.9 % | 0.01 | 89.9 % | +205.7 % | — | 0.0 % | 0.0 % | 19.7 | 75.9 % | 3.6 % | 4.6 (13) | |
| AGX Argan Inc | — | +629 % | 85 10/29 | Stage 2 | A 78 | 5 of 9 | 8.6 $ | Engineering & Construction | Uses AI | — | — | Industrials | 570.40 $ | +135.6 % | +141.6 % | +134.0 % | −4.8 % | +19.2 % | 96 | 86 | 7.0 % | 7.0 % | 0.56 | 50.9 | 16.6 | 8.2 | 16.9 | 17.6 | — | 43.3 | 15.6 % | 20.7 % | 15.5 % | 38.5 % | 9.4 % | — | 36.8 % | +8.1 % | — | 0.4 % | 17.6 % | 8.1 | 108.9 % | 6.7 % | 4.0 (2) |
| TVTX Travere Therapeutics Inc | 08/05 | +82 % | 68 6/22 | Stage 2 | B 64 | 5 of 9 | 5.1 $ | Biotechnology | Uses AI | — | Healthcare | 55.90 $ | +46.4 % | +44.7 % | +261.8 % | −1.8 % | +5.8 % | 96 | 42 | 3.6 % | 4.6 % | 1.11 | — | 76.3 | 9.5 | 51.5 | 292.4 | — | 136.5 | -29.0 % | 56.0 % | -4.0 % | -69.4 % | -6.5 % | 3.35 | 17.8 % | +110.5 % | — | 0.0 % | 0.0 % | -2.7 | 113.4 % | 16.9 % | 4.6 (15) | |
| ANAB AnaptysBio Inc | 08/05 | +114 % | 81 7/22 | Stage 2 | C 45 | 3 of 9 | 1.6 $ | Biotechnology | – | — | — | Healthcare | 53.40 $ | +83.9 % | +97.9 % | +226.0 % | −18.6 % | +63.1 % | 96 | 42 | 5.8 % | 5.3 % | 0.38 | — | 0.0 | 6.8 | 121.9 | 359.5 | — | 22.4 | -135.5 % | 44.6 % | -11.5 % | -114.6 % | 6.8 % | 21.76 | 3.9 % | +157.0 % | — | 0.0 % | 0.0 % | 1.7 | 104.2 % | 37.6 % | 4.4 (12) |
| SITM Sitime Corporation | 08/05 | +172 % | 72 7/25 | Stage 2 | A 77 | 7 of 9 | 15.1 $ | Semiconductors | Sells AI | — | — | Technology | 535.20 $ | +100.1 % | +87.9 % | +163.8 % | −25.1 % | +56.5 % | 95 | 12 | 8.0 % | 7.5 % | 2.91 | — | 71.9 | 39.6 | 12.1 | 278.7 | 3.82 | 3,076.2 | -4.2 % | 55.7 % | -6.4 % | -2.6 % | -2.3 % | 0.00 | 89.6 % | +61.2 % | — | 0.0 % | 0.0 % | 16.1 | 89.0 % | 5.0 % | 3.9 (7) |
| SKYT Skywater Technology Inc | 08/05 | +114 % | 34 4/25 | Stage 2 | B 64 | 4 of 9 | 1.6 $ | Semiconductors | Neutral | — | — | Technology | 32.50 $ | +101.2 % | +99.1 % | +239.9 % | −12.9 % | +7.7 % | 95 | 99 | 5.1 % | 4.8 % | 3.34 | 14.2 | 185.2 | 3.0 | 8.9 | — | — | 11.8 | -3.3 % | 19.4 % | 21.0 % | 95.9 % | -0.4 % | 1.32 | 24.6 % | +29.2 % | — | 0.0 % | 0.0 % | 2.8 | 61.4 % | 7.3 % | 4.2 (5) |
| LSCC Lattice Semiconductor Corporation | 08/03 | +23 % | 72 7/25 | Stage 2 | B 65 | 6 of 9 | 18.3 $ | Semiconductors | Sells AI | — | Technology | 124.30 $ | +96.5 % | +91.7 % | +149.4 % | −8.2 % | +19.3 % | 94 | 93 | 6.8 % | 6.5 % | 1.78 | 887.9 | 69.4 | 31.9 | 22.1 | 117.0 | 0.59 | 226.1 | 15.6 % | 68.4 % | 3.5 % | 2.8 % | 2.5 % | 0.09 | 82.3 % | +2.7 % | — | 0.0 % | 0.0 % | 11.3 | 108.6 % | 6.9 % | 4.5 (14) | |
| OSCR Oscar Health Inc | 08/05 | +84 % | 79 7/22 | Stage 2 | B 64 | 7 of 9 | 9.0 $ | Healthcare Plans | Uses AI | — | — | Healthcare | 31.20 $ | +108.3 % | +97.3 % | +122.2 % | −5.6 % | -19.2 % | 94 | 87 | 5.6 % | 6.6 % | 2.34 | — | 588.2 | 0.7 | 5.7 | 3.2 | — | 0.0 | 15.2 % | 17.4 % | -0.3 % | -2.6 % | 0.1 % | 0.26 | 17.9 % | +27.5 % | — | 0.0 % | 0.0 % | 3.0 | 67.6 % | 8.0 % | 3.3 (7) |
| URGN UroGen Pharma Ltd | 08/06 | +18 % | 69 6/22 | Stage 2 | B 57 | 3 of 9 | 1.8 $ | Biotechnology | Uses AI | — | — | Healthcare | 38.20 $ | +50.1 % | +51.8 % | +100.6 % | −4.7 % | +17.1 % | 94 | 42 | 5.1 % | 5.4 % | 1.58 | — | 0.0 | 13.1 | — | — | — | -2.6 | -39.8 % | 89.9 % | -94.8 % | -1,481.3 % | -27.0 % | — | -49.0 % | +21.5 % | — | 0.0 % | 0.0 % | -8.0 | 100.6 % | 11.9 % | 4.4 (8) |
| LPTH LightPath Technologies Inc | — | +311 % | 87 9/25 | Stage 2 | B 66 | 6 of 9 | 0.7 $ | Electronic Components | Uses AI | — | — | Technology | 10.40 $ | +26.1 % | +61.4 % | +246.8 % | −28.0 % | +53.6 % | 94 | 98 | 8.5 % | 11.6 % | 1.34 | — | 217.4 | 10.4 | — | — | 1.54 | 133.4 | — | 32.1 % | -37.4 % | -28.8 % | -2.8 % | — | — | +17.3 % | — | 0.0 % | 0.0 % | 3.6 | 57.8 % | 15.4 % | 4.8 (5) |
| LASR nLIGHT Inc | 08/06 | +113 % | 73 7/25 | Stage 2 | B 72 | 7 of 9 | 3.9 $ | Semiconductors | – | — | — | Technology | 68.80 $ | +77.1 % | +65.4 % | +227.5 % | −28.2 % | +31.9 % | 93 | 42 | 7.4 % | 8.0 % | 2.30 | — | 135.1 | 13.4 | 8.9 | 175.7 | 1.78 | 3,043.3 | -0.5 % | 31.3 % | -5.1 % | -4.6 % | -2.3 % | 0.08 | 83.2 % | +31.6 % | — | 0.0 % | 0.0 % | 11.0 | 92.1 % | 5.2 % | 4.6 (7) |
| OUST Ouster, Inc. Common Stock | 08/06 | +244 % | 61 6/25 | Stage 2 | B 58 | 6 of 9 | 2.6 $ | Electronic Components | Sells AI | — | Technology | 39.00 $ | +108.7 % | +141.8 % | +66.9 % | −18.8 % | +33.7 % | 93 | 42 | 15.3 % | 13.5 % | 3.18 | — | 0.0 | 14.2 | — | — | — | -0.8 | -39.6 % | 47.7 % | -30.1 % | -25.2 % | -14.7 % | — | 72.2 % | +52.5 % | — | 0.0 % | 0.0 % | -0.7 | 50.0 % | 9.3 % | 4.3 (6) | |
| SEI Solaris Energy Infrastructure, Inc | 07/22 | +327 % | 79 3/10 | Stage 2 | B 73 | 5 of 9 | 5.1 $ | Oil & Gas Equipment & Services | Sells AI | — | Energy | 51.40 $ | +70.3 % | +76.6 % | +59.0 % | −7.8 % | +83.5 % | 92 | 87 | 7.0 % | 7.1 % | 1.18 | — | 384.6 | 7.3 | — | — | 0.94 | 20.2 | 25.8 % | 46.9 % | 6.7 % | 8.7 % | 5.0 % | — | 26.1 % | +98.7 % | — | 0.9 % | 66.7 % | 4.1 | 113.1 % | 26.1 % | 4.9 (8) | |
| AXSM Axsome Therapeutics Inc | 08/03 | +58 % | 78 7/22 | Stage 2 | B 55 | 5 of 9 | 11.6 $ | Biotechnology | – | — | — | Healthcare | 218.00 $ | +32.5 % | +56.9 % | +115.0 % | −8.8 % | +29.5 % | 92 | 42 | 3.6 % | 3.5 % | 0.60 | — | 333.3 | 16.3 | 205.5 | — | — | -14.8 | -32.8 % | 92.6 % | -26.6 % | -349.4 % | -16.8 % | 4.03 | 7.6 % | +65.6 % | — | 0.0 % | 0.0 % | -3.1 | 76.6 % | 9.2 % | 4.7 (19) |
| TGTX TG Therapeutics Inc | 08/03 | +43 % | 53 5/22 | Stage 2 | B 68 | 5 of 9 | 8.0 $ | Biotechnology | Neutral | — | Healthcare | 52.00 $ | +80.9 % | +79.3 % | +46.6 % | −6.5 % | +31.6 % | 90 | 92 | 5.0 % | 4.8 % | 1.60 | 18.9 | 55.2 | 11.5 | 14.2 | — | 1.61 | 54.6 | 17.0 % | 83.1 % | 66.0 % | 112.6 % | 8.6 % | 1.29 | 38.1 % | +87.3 % | — | 0.0 % | 0.0 % | 6.2 | 70.2 % | 29.0 % | 4.3 (9) | |
| CYTK Cytokinetics Inc | 08/06 | +8 % | 68 6/22 | Stage 2 | D 39 | 3 of 9 | 10.4 $ | Biotechnology | Neutral | — | Healthcare | 77.10 $ | +25.9 % | +36.0 % | +104.9 % | −2.6 % | +39.8 % | 88 | 42 | 4.6 % | 4.1 % | 0.42 | — | 117.6 | 97.8 | 57.5 | — | — | -15.8 | -948.7 % | -290.7 % | 0.0 % | -572.2 % | -31.5 % | -1.56 | -64.9 % | +376.6 % | — | 0.0 % | 0.0 % | -7.3 | 118.8 % | 19.4 % | 4.3 (21) | |
| MIRM Mirum Pharmaceuticals Inc | 08/05 | +102 % | 68 6/22 | Stage 2 | C 45 | 3 of 9 | 6.3 $ | Biotechnology | – | — | — | Healthcare | 106.00 $ | +40.6 % | +52.3 % | +105.0 % | −1.9 % | +38.2 % | 86 | 42 | 5.0 % | 5.0 % | 0.49 | — | 39.7 | 11.0 | 28.1 | — | — | 341.2 | -39.5 % | 81.4 % | -140.2 % | -335.8 % | -5.9 % | 1.34 | 27.2 % | +54.7 % | — | 0.0 % | 0.0 % | -5.4 | 114.4 % | 15.6 % | 4.6 (10) |
| FN Fabrinet | 08/17 | +123 % | 78 8/25 | Stage 2 | B 74 | 7 of 9 | 16.5 $ | Electronic Components | – | — | — | Technology | 435.40 $ | +28.2 % | +9.7 % | +34.5 % | −24.2 % | +68.2 % | 82 | 78 | 7.4 % | 7.8 % | 1.20 | 34.5 | 12.8 | 3.9 | 6.3 | 361.0 | 1.19 | 28.7 | 9.9 % | 12.0 % | 9.9 % | 20.0 % | 8.5 % | 0.00 | 65.7 % | +18.6 % | — | 0.0 % | 0.0 % | 11.7 | 113.6 % | 7.4 % | 3.9 (9) |
| ARQT Arcutis Biotherapeutics Inc | 08/05 | +66 % | 54 5/22 | Stage 3 | B 65 | 6 of 9 | 3.4 $ | Biotechnology | – | — | — | Healthcare | 26.90 $ | -9.5 % | -9.1 % | +84.2 % | −16.0 % | +28.7 % | 77 | 42 | 4.7 % | 4.6 % | 1.48 | — | 149.3 | 8.2 | 17.9 | 127.3 | — | 226.7 | -8.6 % | 90.9 % | -0.6 % | -1.4 % | 0.5 % | 0.07 | 41.2 % | +91.3 % | — | 0.0 % | 0.0 % | -0.1 | 110.2 % | 11.6 % | 4.6 (7) |
| NTLA Intellia Therapeutics Inc | 08/06 | -21 % | 69 6/22 | Stage 3 | C 51 | 4 of 9 | 1.6 $ | Biotechnology | – | — | — | Healthcare | 10.70 $ | +69.6 % | +73.2 % | -8.3 % | −43.3 % | +142.4 % | 76 | 42 | 9.3 % | 8.4 % | 1.77 | — | 0.0 | 23.6 | 2.4 | — | — | -5.5 | -668.1 % | -349.0 % | 0.0 % | -56.3 % | -30.1 % | 0.13 | 81.8 % | +16.9 % | — | 0.0 % | 0.0 % | -3.7 | 76.7 % | 41.3 % | 4.3 (29) |
| RYZ Ryerson Holding Corporation | 08/04 | -7 % | — | Stage 2 | B 56 | 5 of 9 | 0.0 $ | Metal Fabrication | – | — | — | Industrials | 27.80 $ | +11.0 % | -2.0 % | +39.1 % | −10.0 % | +4.2 % | 73 | 50 | 4.6 % | 4.2 % | 1.68 | — | 3.5 | — | 1.0 | — | — | 34.0 | 2.2 % | 17.3 % | -0.9 % | -4.3 % | 0.0 % | 1.01 | 34.4 % | -0.6 % | — | 3.1 % | 118.7 % | 6.4 | 96.0 % | 3.5 % | — |
| ALHC Alignment Healthcare LLC | 07/29 | +85 % | 68 6/22 | Stage 3 | B 72 | 7 of 9 | 3.0 $ | Healthcare Plans | Uses AI | — | — | Healthcare | 14.90 $ | +9.7 % | +21.5 % | +7.8 % | −4.9 % | +65.2 % | 72 | 42 | 4.6 % | 5.7 % | 1.05 | 142.3 | 204.1 | 0.7 | 14.2 | 16.1 | — | 31.3 | 1.3 % | 12.6 % | 0.9 % | 12.5 % | 3.1 % | 1.60 | 16.4 % | +46.1 % | — | 0.0 % | 0.0 % | 3.3 | 106.7 % | 12.3 % | 4.1 (11) |
| RYTM Rhythm Pharmaceuticals Inc | 08/04 | +170 % | 39 4/22 | Stage 3 | B 57 | 5 of 9 | 6.7 $ | Biotechnology | – | — | — | Healthcare | 99.30 $ | -0.8 % | -2.0 % | +16.5 % | −11.4 % | +39.8 % | 70 | 42 | 5.8 % | 4.8 % | 1.88 | — | 0.0 | 31.0 | 55.4 | — | — | -12.6 | -87.1 % | 89.4 % | -93.3 % | -101.2 % | -29.8 % | 1.85 | 27.8 % | +45.8 % | — | 0.0 % | 0.0 % | -4.6 | 110.0 % | 14.1 % | 4.7 (12) |
| MDGL Madrigal Pharmaceuticals Inc | 08/04 | +39 % | 78 7/22 | Stage 2 | B 57 | 2 of 9 | 10.9 $ | Biotechnology | – | — | — | Healthcare | 467.30 $ | -11.8 % | -12.5 % | +54.5 % | −16.5 % | +46.1 % | 68 | 42 | 4.0 % | 4.0 % | -1.06 | — | 666.7 | 8.5 | 19.8 | — | — | -8.3 | -29.8 % | 91.5 % | -25.3 % | -49.4 % | -17.8 % | 0.64 | 44.3 % | +432.1 % | — | 0.0 % | 0.0 % | 1.3 | 106.5 % | 10.5 % | 4.5 (15) |
| TBPH Theravance Biopharma Inc | 08/11 | +19 % | 55 5/22 | Stage 1 | B 66 | 5 of 9 | 0.8 $ | Biotechnology | – | — | — | Healthcare | 16.90 $ | -9.3 % | -8.9 % | +51.1 % | −17.3 % | +4.5 % | 64 | 42 | 2.8 % | 2.3 % | 0.17 | 7.7 | 7.9 | 7.7 | 3.0 | 3.2 | — | 3.7 | — | 71.0 % | 104.3 % | 50.2 % | 0.8 % | 0.25 | — | +66.9 % | — | 0.0 % | 0.0 % | 6.3 | 99.1 % | 13.3 % | 3.8 (4) |
| SNDX Syndax Pharmaceuticals Inc | 08/03 | -2 % | 55 5/22 | Stage 1 | B 60 | 3 of 9 | 1.7 $ | Biotechnology | – | — | — | Healthcare | 19.10 $ | -6.7 % | +0.8 % | +92.0 % | −22.6 % | +106.6 % | 63 | 42 | 4.7 % | 4.4 % | 0.37 | — | 0.0 | 7.9 | — | — | — | -105.3 | -52.7 % | -23.2 % | -112.0 % | -189.5 % | -25.1 % | — | 8.8 % | +627.8 % | — | 0.0 % | 0.0 % | -4.3 | 116.0 % | 23.9 % | 4.7 (12) |
| ASTS Ast Spacemobile Inc | 08/10 | +321 % | 87 9/25 | Stage 1 | C 54 | 5 of 9 | 23.0 $ | Communication Equipment | – | — | — | Technology | 59.00 $ | +0.3 % | +11.2 % | +10.9 % | −51.0 % | +36.4 % | 62 | 42 | 10.4 % | 11.6 % | 2.68 | — | 0.0 | 270.9 | 8.8 | — | — | -2.3 | -1,014.0 % | 44.8 % | 0.0 % | -37.8 % | -6.3 % | 1.44 | 34.4 % | +1,505.2 % | — | 0.0 % | 0.0 % | 5.9 | 47.2 % | 19.9 % | 3.2 (11) |
| BBIO BridgeBio Pharma Inc | 08/04 | +113 % | 68 6/22 | Stage 1 | C 54 | 3 of 9 | 15.7 $ | Biotechnology | – | — | — | Healthcare | 80.10 $ | -10.3 % | -5.9 % | +69.4 % | −18.0 % | +31.4 % | 59 | 42 | 3.7 % | 4.0 % | 0.95 | — | 0.0 | 27.0 | 142.2 | — | — | -9.4 | -54.5 % | 95.1 % | -124.4 % | -1,789.7 % | -28.0 % | -1.49 | -165.5 % | +126.3 % | — | 0.0 % | 0.0 % | -7.9 | 103.2 % | 14.7 % | 4.4 (19) |
| MP MP Materials Corp | 08/06 | +58 % | 50 5/23 | Stage 4 | B 62 | 6 of 9 | 7.5 $ | Other Industrial Metals & Mining | – | — | — | Basic Materials | 41.40 $ | +16.6 % | +0.4 % | -32.7 % | −44.5 % | +87.9 % | 55 | 13 | 5.5 % | 6.5 % | 1.86 | — | 500.0 | 21.7 | 3.8 | — | — | 224.7 | -7.9 % | 37.2 % | -20.5 % | -4.2 % | -2.1 % | 0.44 | 62.0 % | +35.1 % | — | 0.0 % | 0.0 % | 8.0 | 70.2 % | 17.4 % | 4.4 (9) |
| CVI CVR Energy Inc | 07/29 | +6 % | 93 4/10 | Stage 4 | C 49 | 5 of 9 | 3.7 $ | Oil & Gas Refining & Marketing | – | — | — | Energy | 35.60 $ | +8.9 % | +8.6 % | +35.5 % | −34.5 % | -17.4 % | 23 | 9 | 4.9 % | 5.0 % | 0.82 | — | 32.5 | 0.4 | — | 9.4 | 0.71 | 5.9 | — | 10.9 % | 0.8 % | 4.7 % | 5.5 % | — | — | -5.9 % | — | 1.1 % | 14.5 % | 3.6 | 102.3 % | 17.9 % | 2.6 (7) |
| ALNY Alnylam Pharmaceuticals Inc | 07/30 | +17 % | 38 4/22 | Stage 4 | A 79 | 7 of 9 | 27.3 $ | Biotechnology | Uses AI | — | Healthcare | 205.50 $ | -27.5 % | -26.7 % | -47.6 % | −40.8 % | +88.0 % | 17 | 42 | 3.4 % | 3.4 % | 0.27 | 51.2 | 23.4 | 5.7 | 25.4 | — | 0.37 | 23.0 | 23.0 % | 79.7 % | 16.1 % | 90.4 % | 12.3 % | 1.18 | 21.0 % | +65.2 % | — | 0.0 % | 0.0 % | 4.2 | 102.1 % | 5.8 % | 4.2 (30) | |
| VRDN Viridian Therapeutics Inc | 08/05 | -11 % | 39 4/22 | Stage 4 | B 65 | 2 of 9 | 2.1 $ | Biotechnology | – | — | — | Healthcare | 18.90 $ | -44.5 % | -41.8 % | +8.0 % | −49.3 % | +91.1 % | 13 | 42 | 5.1 % | 5.1 % | 0.90 | — | 1.0 | 30.1 | 4.1 | — | — | -3.2 | -82,389.4 % | -378.9 % | 0.0 % | -58.1 % | -33.3 % | 0.08 | 80.6 % | +23,359.9 % | — | 0.0 % | 0.0 % | 4.8 | 109.2 % | 17.8 % | 4.4 (16) |
| INSM Insmed Inc | 08/06 | +45 % | 53 5/22 | Stage 4 | B 60 | 4 of 9 | 21.4 $ | Biotechnology | – | — | — | Healthcare | 98.60 $ | -41.3 % | -41.0 % | -8.1 % | −50.9 % | +99.0 % | 12 | 42 | 4.8 % | 4.9 % | 0.78 | — | 16.4 | 26.1 | 30.3 | — | 1.09 | -6.0 | -65.5 % | 81.8 % | -144.4 % | -294.5 % | -31.1 % | 1.32 | 34.0 % | +66.7 % | — | 0.0 % | 0.0 % | -4.9 | 105.7 % | 6.1 % | 4.8 (21) |
| CAI Caris Life Sciences, Inc. Common Stock | 08/11 | — | — | Stage 4 | B 66 | 6 of 9 | 0.0 $ | Biotechnology | – | — | — | Healthcare | 15.70 $ | -34.8 % | -35.1 % | -44.2 % | −56.0 % | +48.8 % | 11 | 50 | 5.9 % | 6.5 % | — | — | 49.3 | — | 9.0 | — | — | 44.1 | 2.4 % | 68.9 % | 3.8 % | 28.3 % | 9.3 % | 0.73 | 51.1 % | +97.0 % | — | 0.0 % | 0.0 % | 2.6 | 56.7 % | 10.1 % | — |
Price Chart
Quarterly Figures
No quarterly data available.
Frequently Asked Questions
Ben Bennett's Focus List: quality growth stocks in strong industries. The industry ranks in the top 40 by 12-month strength, expected earnings per share (EPS) growth for next year is above 25%, revenue grew by an average of more than 30% over the last 2 quarters, price above $10, and sufficiently liquid (~250K shares).
All scanners are recalculated daily across the entire stock universe — most recently on 3. August 2026. The data basis is fundamental data and SEC filings (10-K annual reports and 10-Q quarterly reports).
Currently, 41 stocks pass this scanner's criteria (as of 3. August 2026).
Global filters: market cap of $50B or less (mega caps are cut from every scanner); 10- and 30-day ADR must be ≥ 1% (too little movement gets cut); names after a reverse split (distorted price history) and names with a red Stress RS (rating ≤ 30 — weak on stress days) are excluded.
Related scanners
- Ben Bennett: Power Screen
- Dan Zanger: Leader
- EPS & Revenue Power
- EPS Acceleration
- High Revenue Growth
- Jim Roppel: 20/20 Screen
- Joshua
- Martin Zweig: Growth with Reason
- Matt Caruso: Sales Leader
- Patrick Walker: 30% EPS Growth
- Patrick Walker: 40, 40 Screen
- Quality Growth
- Small Caps with Growth
- Ted Zhang: Super Stock Universe
- Thomas' Favorites
- Triple-Digit Revenue Growth
- William O'Neil (CAN SLIM)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.